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Microarray-Based Mutation Detection and Phenotypic
Characterization of Patients with Leber
Congenital Amaurosis
Suzanne Yzer,1,2,3 Bart P. Leroy,3,4,5 Elfride De Baere,5 Thomy J. de Ravel,6
Marijke N. Zonneveld,2 Krysta Voesenek,2 Ulrich Kellner,7 Jose P. Martinez Ciriano,1
Jan-Tjeerd H. N. de Faber,1 Klaus Rohrschneider,8 Ronald Roepman,2
Anneke I. den Hollander,2 Johannes R. Cruysberg,9 Franc¸oise Meire,4 Ingele Casteels,10
Norka G. van Moll-Ramirez,11 Rando Allikmets,12 L. Ingeborgh van den Born,1 and
Frans P. M. Cremers2
PURPOSE. To test the efficiency of a microarray chip as a diag-
nostic tool in a cohort of northwestern European patients with
Leber congenital amaurosis (LCA) and to perform a genotype–
phenotype analysis in patients in whom pathologic mutations
were identified.
METHODS. DNAs from 58 patients with LCA were analyzed
using a microarray chip containing previously identified dis-
ease-associated sequence variants in six LCA genes. Mutations
identified by chip analysis were confirmed by sequence analy-
sis. On identification of one mutation, all protein coding exons
of the relevant genes were sequenced. In addition, sequence
analysis of the RDH12 gene was performed in 22 patients.
Patients with mutations were phenotyped.
RESULTS. Pathogenic mutations were identified in 19 of the 58
patients with LCA (32.8%). Four novel sequence variants were
identified. Mutations were most frequently found in CRB1
(15.5%), followed by GUCY2D (10.3%). The p.R768W muta-
tion was found in 8 of 10 GUCY2D alleles, suggesting that it is
a founder mutation in the northwest of Europe. In early child-
hood, patients with AIPL1 or GUCY2Dmutations show normal
fundi. Those with AIPL1-associated LCA progress to an RP-like
fundus before the age of 8, whereas patients with GUCY2D-
associated LCA still have relatively normal fundi in their mid-
20s. Patients with CRB1mutations present with distinct fundus
abnormalities at birth and consistently show characteristics of
RP12. Pathogenic GUCY2Dmutations result in the most severe
form of LCA.
CONCLUSIONS. Microarray-based mutation detection allowed the
identification of 32% of LCA sequence variants and represents
an efficient first-pass screening tool. Mutations in CRB1, and to
a lesser extent, in GUCY2D, underlie most LCA cases in this
cohort. The present study establishes a genotype-phenotype
correlation for AIPL1, CRB1, and GUCY2D. (Invest Ophthal-
mol Vis Sci. 2006;47:1167–1176) DOI:10.1167/iovs.05-0848
In 1869, Theodor Leber reported an “intrauterine” form ofretinitis pigmentosa (RP).1 These children, mostly from con-
sanguineous marriages, were congenitally blind without any
retinal abnormalities. Later, many displayed a fundus picture
typically found in other retinal dystrophies such as RP. This
condition is now known as Leber congenital amaurosis (LCA),
a clinically and genetically heterogeneous disorder character-
ized by severe bilateral congenital retinal blindness, with nys-
tagmus and a nondetectable ERG before the age of 1 year.2
Thus far, mutations in seven genes (AIPL1, CRB1, CRX,
GUCY2D, RDH12, RPE65, and RPGRIP1) have been shown to
cause LCA, accounting for 35% to 47.5% of cases of LCA.3–12
Mutations in all these genes, except RPGRIP1, have also been
found to cause other, clinically less severe retinal diseases,
such as cone–rod dystrophy (CRD) or RP, with autosomal
dominant inheritance shown in several cases.13,14
A specific subtype of RP with a distinct phenotype caused
by mutations in the CRB1 gene is usually referred to as RP12.
The clinical characteristics of this autosomal recessive disease
include early central and peripheral visual loss, hyperopia,
maculopathy, nummular rather than spicular pigmentation,
and limited attenuation of vessels and para-arteriolar preserva-
tion of the RPE (PPRPE). Patients frequently have a Coats-like
exudative vasculopathy.3,4
At present, no treatment is available for LCA or allied retinal
dystrophies. However, several treatment strategies are under
study, and some have reached the human clinical trial
phase.15–19 Although all other potential treatments would also
benefit from more profound knowledge of the underlying
genetic defects and disease mechanisms, this is especially true
for gene replacement therapy. Although the identification of
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the causal mutations in known LCA genes is technically not
difficult (e.g., using sequence analysis), the genetic heteroge-
neity and complexity of several LCA genes has hampered their
routine molecular analysis. For this purpose, high-throughput
techniques are necessary. One such technique, allele-specific
primer extension (APEX), has been used in conjunction with a
genotyping microarray chip to detect mutations in the ABCA4
gene. Mutations in this gene are associated with Stargardt
disease, autosomal recessive cone–rod dystrophy, a panretinal
autosomal recessive rod–cone dystrophy, and possibly age-
related macular degeneration.20–22 This chip has been a robust
and cost-effective screening tool.23,24 A similar microarray chip
was recently developed for genotyping 300 known muta-
tions in six LCA genes.5
In this study, we ascertained 58 unrelated patients with
LCA, who predominantly live in Belgium and the Netherlands,
and we identified the molecular causes in one third of the cases
by means of the microarray chip. Clinical data of patients with
mutations in the known LCA genes were analyzed retrospec-
tively and all but three were re-examined for the purpose of
this study to establish genotype–phenotype correlations.
METHODS
Patients
DNA samples from 58 unrelated white patients with a clinical diagnosis
of LCA were collected from Belgium (36 cases; Ghent University
Hospital, University Hospital Leuven), The Netherlands (20 cases; Rot-
terdam Eye Hospital, Rotterdam; Sensis International, Grave; and Rad-
boud University Nijmegen Medical Centre, Nijmegen), and Germany (2
cases; University Hospital Heidelberg and the University School of
Medicine, Berlin). All procedures were approved by the ethics boards
of the collaborating institutes and adhered to the tenets of the Decla-
ration of Helsinki. All samples were acquired after written informed
consent was obtained from the patient or in the case of children, their
legal guardians.
LCA was defined as bilateral visual loss noticed before the age of 6
months, accompanied by wandering nystagmus and an undetectable or
significantly reduced electroretinogram (ERG). Only patients who had
not been genotyped previously were included in this study. Patients
with a juvenile-onset RP (onset after 1 year of age) or a syndromic form
of LCA, such as Joubert syndrome, were excluded.
Microarray Mutation Analysis
Standard protocols were used to extract DNA from peripheral blood
leukocytes.25
The LCA microarray chip contained sense and antisense oligonu-
cleotides (25-mers) corresponding to 301 previously identified disease-
associated sequence variants in six of seven currently known LCA
genes: AIPL1 (25 sequence variants), CRB1 (68 sequence variants),
CRX (29 sequence variants), GUCY2D (66 sequence variants), RPE65
(81 sequence variants), and RPGRIP1 (32 sequence variants).26 In
addition, the chip contained disease-associated sequence variants in
two early-onset RP genes: LRAT (two sequence variants) and MERTK
(three sequence variants).
In brief, 68 DNA fragments containing the 301 sequence variants
were amplified, and PCR-products were visualized on agarose gels. The
PCR products were pooled, denatured, and hybridized to the microar-
ray chips. The sequence variants were detected by a sequence-specific
primer extension using dideoxynucleotides. For technical details re-
garding the allele-specific primer extension (APEX) method, see Jaak-
son et al.23 The results obtained from the LCA microarray chip were
confirmed through bidirectional sequencing of the relevant amplicons
(ABI3730 and ABI3100 Genetic Analyzers; Applied Biosystems, Inc.
[ABI], Foster City, CA). Automatic analysis was performed by a base-
caller (ABI).
At the time of mutation chip analysis, RDH12 had not yet been
identified. We therefore sequenced the seven protein coding exons of
RDH12 in all Dutch and German patients.27
In those patients in whom one mutation was identified, the entire
gene was sequenced. Primers and PCR conditions have been de-
scribed.3,9,10,28 Four novel sequence changes were identified. One of
them was a new GUCY2D (c.2837C3T; p.A946V) missense mutation
that was subsequently tested in DNA from 93 anonymous healthy
Dutch control individuals by restriction fragment length polymor-
phism (RFLP) analysis. BstUI cuts the normal but not the mutant PCR
product containing exon 15 (288 bp) in 154- and 134-bp fragments.
When parents or unaffected siblings were available, segregation anal-
ysis was performed.
Phenotyping
In patients with presumed pathologic sequence variants, clinical data
were retrospectively collected. In most cases, follow-up clinical infor-
mation was available, and we used the data from the first and last
examinations. At the first visit, parents and patients were questioned
about the age of onset of symptoms such as night blindness, photo-
phobia, and photoattraction. A family history was taken and questions
concerning pregnancy, birth, birth defects, and consanguinity were
asked. Pupillary reactions were observed, and nystagmus and photo-
phobia were evaluated. Ophthalmic examination included best-cor-
rected, age-appropriate visual acuity testing and measurement of ob-
jective refractive error after cycloplegia. The anterior segment was
examined by slit lamp biomicroscopy followed by funduscopy after
pupillary dilation. Goldmann visual field results were obtained when
possible. ERGs made according to pediatric protocols were obtained in
all patients but three at the collaborating institutes. Color vision was
tested in four patients with a low-vision edition of the Panel D-15 test
(large surfaces) under bright daylight illumination (3500 lux; color
temperature of approximately 4500 K), higher than levels normally
used in color vision testing (1600–1900 lux; color temperature of 6500
K).29 Images of the fundus were acquired with a fundus photography
system (Topcon, Tokyo, Japan). Interpretable autofluorescence images
were obtained in two patients with the same system. Interpretable
autofluorescence and red-free images were acquired with the Heidel-
berg Retinal Angiograph (HRA2; Heidelberg Engineering, Heidelberg,
Germany) in one patient.
RESULTS
Genotypes
The molecular genetic results are summarized in Table 1. The
microarray chip allowed the identification of homozygous or
compound heterozygous sequence variants in 14 of 58 patients
and single heterozygous sequence variants in 6 of 58. All
variants were confirmed by using sequence analysis of the
relevant exons. In the six heterozygous patients, the protein-
encoding exons of the respective genes were sequenced, and
four novel sequence variants were identified.
Phenotypes
All available clinical data of the first visit as well as funduscopic
findings at the last examination are summarized in Table 2. In
the following sections, a summary of relevant clinical informa-
tion is provided. All patients had an ERG performed before the
age of 12 months, which was nonrecordable in all except
patients 21394, 24105, and 246V1, in whom the ERG was
severely reduced.
AIPL1
Genotypes. All three patients with mutations in AIPL1
were homozygous for p.R278W.
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Phenotypes. Over a 15-year period, the visual acuity of
patient 14962 remained stable. When he was initially examined
during his first year of life because of nystagmus, funduscopy
was normal. At the age of 15, a bull’s eye maculopathy as well
as increased pigment spicules in the periphery were observed.
Patient 20143 was first examined after he failed to fix and
follow objects at the age of 3 months. He was mentally hand-
icapped, and he regularly poked his eyes (oculodigital sign)
and had weak and slow pupillary reactions. At the age of 7.5
years, visual acuity (VA) was 0.003 (OU) and the lenses showed
a nuclear opacity. Funduscopy revealed a pale optic disc and
attenuation of the retinal vasculature, with neither obvious
maculopathy nor peripheral intraretinal pigmentation.
When patient 2040V1 was first seen at the age of 5 months
because of nystagmus, funduscopy revealed diffuse alterations
of the retinal pigment epithelium and mild attenuation of
vessels. She was night-blind and preferred a well-lit environ-
ment. At 8 years of age, she displayed nystagmus with a pre-
dominant slow horizontal component. Best-corrected visual
acuity was 0.02 with a refraction of 7.5 OU. Axial length was
19.6 mm OD and 19.9 mm OS. On funduscopy, a bull’s eye
maculopathy was present with diffuse RPE alterations with
only limited spicular intraretinal pigmentation (Fig. 1a). Sub- or
deep intraretinal hyperfluorescent spots were seen on
autofluorescence imaging (Fig. 1b).
CRB1
Genotypes. Eight of nine patients carrying mutations in
CRB1 were compound heterozygous. The p.C984Y and
p.K801X alleles were found in five and four patients, respec-
tively. Two patients with CRB1 mutations were compound
heterozygous for mutations p.C948Y and c.28425G3A, and
one of them (patient 21551) also carried the p.V96I AIPL1
sequence variant. The latter sequence change was not consid-
ered to be pathologic, because it was identified in heterozy-
gous form in 11 of 186 healthy control subjects. Two new
nonsense mutations were identified in CRB1: p.Q362X and
p.Q1222X.
Phenotypes. Patient 21394 first presented at the age of 3
months with torticollis presumably related to nystagmus. His
fundus was then normal. At the age of 5 years, his VA had
decreased slightly from 0.05 to 0.02 OU. On funduscopy, he
had several characteristics of RP12, including pink optic discs,
relatively normal arterioles, and extensive RPE atrophy, both in
the posterior pole and in the periphery, with nummular pig-
mentations. He lacked PPRPE.
Patient 21405 was first examined in the first year of life
because of night blindness. At 0.17 OD and 0.20 OS, her visual
acuity was then better than any other patient in this entire
study cohort. Funduscopy showed macular and peripheral
mild RPE changes as the only abnormalities. At age 14, the
typical RP12 phenotype was seen with macular and optic disc
edema, a dysplastic macular region, perivascular sheathing,
mild arteriolar attenuation, and PPRPE (Fig. 1i). Goldmann
perimetry performed at the time showed an absolute ring
scotoma with relatively well preserved central fields (50° di-
ameter OD, 30° OS).
The first symptom noticed in patient 21551 was a failure to
develop eye contact at age 4 months. When the patient was
initially seen at that age, ERG responses were absent. Very
limited clinical data were available, but at 13 years of age, he
had very poor pupillary reactions with a residual visual acuity
and stable hypermetropic refraction. Goldmann visual field
testing showed preservation of the central 15° field, albeit with
a considerable decrease in sensitivity.
LCA was diagnosed in patient 21554 at 2 months of age after
the oculodigital sign had been noticed and ERG responses
were absent. When examined at age 3, she preferred a well-lit
environment and was reported unable to see in dim light. She
had a predominantly horizontal slow nystagmus and esotropia
of the right eye. The VA was virtually stable when she was
examined at the age of 12. She had by then lost nearly all ability
to recognize basic colors. A small posterior lenticular opacity
was present inferior to the visual axis. On funduscopy she
showed the RP12 phenotype and over a 9-year period both the
aspect and size of the dysplastic regions in both maculae
TABLE 1. Mutations Identified in Patients with LCA and Results from Segregation Analysis
Gene Patient
Variant 1 Variant 2 Segregation
of
MutationsExon Nucl. Change AA Change Exon Nucl. Change AA Change
AIPL1 14962 6 c.834G3A p.W278X 6 c.834G3A p.W278X NT
20143* 6 c.834G3A p.W278X 6 c.834G3A p.W278X Yes
2040V1 6 c.834G3A p.W278X 6 c.834G3A p.W278X Yes
CRB1 21394 9 c.2843G3A p.C948Y 9 c.3664C3T p.Q1222X Yes
21405 9 c.2843G3A p.C948Y 7 c.2234C3T p.T745M Yes
21551 9 c.2843G3A p.C948Y 8 c.2842  5G3A splice defect Yes
21554 9 c.2843G3A p.C948Y 8 c.2842  5G3A splice defect Yes
21669 9 c.2843G3A p.C948Y 7 c.2234C3T p.T745M Yes
246V1 7 c.2401A3T p.K801X 5 c.1084C3T p.Q362X NT
278V1 7 c.2401A3T p.K801X 8 c.2688T3A p.C896X NT
2148V1 7 c.2401A3T p.K801X 8 c.2688T3A p.C896X Yes
3460V1 7 c.2401A3T p.K801X — — — NA
GUCY2D 441 8 c.1694T3C p.F565S 12 c.2302C3T p.R768W Yes
20955 12 c.2302C3T p.R768W 12 c.2302C3T p.R768W Yes
21067* 12 c.2302C3T p.R768W 15 c.2837C3T p.A946V Yes
21557 12 c.2302C3T p.R768W 12 c.2302C3T p.R768W Yes
22018 12 c.2302C3T p.R768W 12 c.2302C3T p.R768W NT
22597* 8 c.1694T3C p.F565S 8 c.1694T3C p.F565S NT
RPE65 23207 5 c.370C3T p.R124X 14 c.1590delC p.F530fs Yes
Bold sequence variants: novel pathogenic mutations identified by sequence analysis. —, no second allele found; AA, amino acid; NA, not
applicable; Nucl., nucleotide; NT, not tested.
* Consanguineous parents.
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FIGURE 1. Fundus photographs of patients with LCA. (a) Patient 2040V1 (AIPL1 p.W278X/p.W278X) at age 9: composite of fundus of the left eye
(OS), showing macular dystrophy in a bull’s eye pattern, diffuse RPE alterations with scarce intraretinal pigment migration with spicular aspect,
and sub- or deep intraretinal fine white deposits predominantly along vascular arcades. (b) Patient 2040V1 (AIPL1 p.W278X/p.W278X) at age 9:
composite of autofluorescence image of fundus of right eye (OD), showing presence of sub- or deep intraretinal fine white deposits predominantly
along vascular arcades that hyperfluoresce. (c) Patient 23207 (RPE65 p.R124X/p.F530fs) at age 6.5 years: a relatively hypopigmented fundus of OS
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remained virtually stable (Figs. 1d, 1f). Perivascular sheathing
of retinal vessels around the optic disc was better seen on
red-free imaging (Fig. 1e).
Patient 21669 was born with palatoschisis. The disease was
diagnosed when he was 6 months of age, when strabismus was
noted and ERG responses were absent. When seen last at age
10 years, he showed funduscopic characteristics of RP12 with
Coats-like vasculopathy in both eyes. PPRPE was not present.
Patient 246V1 had received a diagnosis at age 4 months
after presenting with nystagmus. Over 30 years, his VA of 0.01
OU and hypermetropia with pronounced astigmatism of 5.0
D (5.5 D) 30° OD and 4.5 D (5.25 D) 140° OS has
remained fairly stable. When last seen at age 30, he preferred
bright light. His nystagmus was horizontal. A subcapsular cat-
aract was present in both eyes (OS  OD). Despite the con-
siderable astigmatism, there were no signs of keratoconus.
Over a period of 16 years, some of the funduscopically visible
RP12 characteristics, such as nummular hyperpigmentation
and subretinal deposits, increased (Figs. 1g, 1h). He had basic
color vision as tested on a low-vision Panel D-15 test, when
ambient light was sufficiently intense.
In patient 278V1 the oculodigital sign had been noted since
childhood. At the age of 34 years, her VA had decreased slightly
to 0.005 OU due to scarring after acute hydrops of her bilateral
keratoconus. Her vision was better in bright light. She had
pronounced enophthalmos, esotropia, and nystagmus, which
also had a predominant horizontal component. On fundus-
copy, a steady increase in the white subretinal deposits and
nummular pigmentation was noted over the years. The size of
the macular aplastic lesions had not changed since birth.
A diagnosis of LCA was made in patient 2148V1 at age 4
months because of a failure to fix and follow objects. ERG
responses were absent. At the age of 8 years, he preferred
bright light and had a VA of only hand movements. He had
enophthalmos due to frequent eye-poking, and he displayed
horizontal nystagmus. Slit lamp examination findings stayed
unremarkable over the years. The nummular intraretinal pig-
mentation and number of deposits increased. There was some
perception of colors, as measured with a modified Panel D-15
test.
Patient 3460V1 was a 55-year-old blind woman who was
severely mentally retarded due to meningitis in the first weeks
of life. When LCA was diagnosed at age 3 months she was
failing to fix and follow objects, and ERG responses were
absent. She frequently poked her eyes. After several painful
episodes of acute corneal hydrops consequent from keratoco-
nus, her right eye was enucleated at age 53. Because of the
presence of a dense cataract, funduscopy of the left eye was
impossible, and, because of mental retardation, visual acuity
was unmeasurable.
CRX
In patient 22654, a heterozygous sequence change (p.Y142C)
in the CRX gene was identified. Sequencing of the entire gene
confirmed the presence of this variant but did not reveal a
second change. Segregation analysis of the unaffected consan-
guineous parents revealed the mother to be homozygous for
this sequence change and the father to carry two wild-type
alleles. To rule out the possibility that we failed to amplify a
wild-type allele by PCR in the mother due to a polymorphic
sequence change underneath one of the amplicon primers, we
repeated the sequence analysis with different primers and
confirmed the homozygosity of the p.Y142C variant in the
DNA of the patients’ mother. The maternal grandparents had
normal vision. The sequence change was therefore considered
a benign variant. Therefore, we conclude that 33 of 116 disease
alleles were identified by chip analysis alone.
GUCY2D
Genotypes. The p.R768W mutation represented 8 of 12
alleles in five of six patients with GUCY2D-related LCA. One of
the compound heterozygotes carried a novel mutation,
p.A946V, which was absent in 93 control individuals.
Phenotypes. LCA was diagnosed in patient 441 at the age
of 3 months after she failed to fix and follow objects. When
examined at the age of 1 year, she frequently poked her eyes.
She was able to follow objects, provided she was in a well-lit
environment, after having started staring at lights at the age of
5 months. Her fundus examination had been unremarkable
since birth.
Patient 20955 received a diagnosis of LCA in the weeks after
birth because of eye poking, which she continued until the age
of 8 years. ERG responses were absent. At the age of 23 she
preferred a dim environment. Her fundus was fairly normal,
apart from arteriolar attenuation.
After a diagnosis because of strabismus at 6 months of age,
patient 21067 was photophobic as a child, which markedly
decreased later in life, and at the age of 22 she instead pre-
ferred bright light. She had esotropia of the left eye. Apart from
arteriolar attenuation and mild RPE alterations in the fovea, the
fundus examination was unremarkable (Fig. 1j).
LCA was diagnosed in patient 21557 at the age of 4 months,
because he failed to fix and follow objects. His ERG responses
were absent, and he was completely blind. At the age of 39, he
had a divergent strabismus as well as bilateral dense cataracts
that precluded funduscopy.
A diagnosis was made in patient 22018 at the age of 2
months after he failed to fix and follow objects. He showed the
oculodigital sign and episodic head turns. At the age of 2.5
years, there was no perception of light, and his pupils were
with mild attenuation of arterioles and diffuse RPE alterations. (d) Patient 21554 (CRB1 p.C948Y/c.28425G3A): posterior pole of OD at age 7
showing edematous optic disc with preretinal fibrosis, perivascular sheathing, macular dysplasia, and fine, white, deep intra- or subretinal deposits.
(e) Patient 21554 (CRB1 p.C948Y/c.28425G3A): red-free image of optic disc and inferotemporal peripapillary area of OS at age 12 showing a
better visualization of perivascular fibrotic sheathing. (f) Patient 21554 (CRB1 p.C948Y/c.28425G3A): composite of fundus of OD at age 12
showing edematous optic disc with preretinal fibrosis and perivascular fibrotic sheathing without clear PPRPE apart from vessel inferonasal to OD;
macular dysplasia remains stable, whereas there is fine nummular intraretinal hyperpigmentation with fine, white, deep intra- or subretinal deposits
in the mid- and far periphery. (g) Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus picture of OS at age 14: Note that optic disc is fairly
normal; the macula is dysplastic; limited vascular attenuation with relative PPRPE; nummular hyperpigmentation in the macula and the retinal
periphery and multiple white subretinal deposits scattered throughout the fundus. (h) Patient 246V1 (CRB1 p.K801X/p.Q362X): composite fundus
picture of OS at age 30 shows limited visibility due to subcapsular cataract, stable dysplasia of the macula but a dramatic increase in the number
of nummular pigmentations in the posterior pole, vascular attenuation, mixed nummular and spicular hyperpigmentation in the retinal periphery,
and multiple white subretinal deposits scattered throughout the fundus. (i) Patient 21405 (CRB1 p.C948Y/p.T745M) at age 14: composite of fundus
of OD showing edematous optic disc with perivascular sheathing, mild narrowing of the arterioles showing tortuosities with subretinal white dots
along arterioles with PPRPE, macular aplasia, atrophic RPE in the periphery with PPRPE, and nummular and a few spicular pigmentations. The
posterior pole showed edema with a few intraretinal hemorrhages. (j) Patient 21067 (GUCY2D p.R768W/p.A946V): composite of fundus of OD
at age 22 showing arteriolar attenuation and mild RPE alterations in the fovea.
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wide and responded only minimally to bright light. Fundus-
copy was normal.
Patient 22597 belonged to a family with 10 siblings, three of
which had LCA. Therefore, an early clinical diagnosis was
made soon after birth. There was congenital nystagmus, and
her vision had never been better than light perception. Re-
cently, she had acute hydrops of a keratoconus in one eye.
When she was 25 years of age, attenuation of the retinal
vasculature was the only abnormality noted on funduscopy.
RPE65
Genotype. In this cohort, one patient had LCA due to
mutations in RPE65. The p.R124X mutation was identified by
the chip analysis, and a novel frameshift mutation (p.F530fs)
was identified by sequence analysis.
Phenotype. Patient 23207 did not make eye contact at 2
months and had night blindness at the age of 6 years. He had
a very poor VA in the first year of life, with gradual improve-
ment up to 0.16 OD and 0.12 OS, with a refraction of2.5 OD
and 3.5 OS at the age of 6 years. Nystagmus was present. He
had a visual field of 60° and perceived the main colors. His
fundus was relatively hypopigmented, with mild attenuation of
the arterioles and diffuse RPE alterations (Fig. 1c).
DISCUSSION
The mutation-screening protocol applied in this study con-
sisted of an initial microarray-based mutation analysis, followed
by sequence analysis of genes in those patients with LCA in
whom single heterozygous mutations were identified. In addi-
tion, mutations in patients who were either homozygous or
compound heterozygous were confirmed by sequence analy-
sis.
This approach allowed the identification of 37 disease al-
leles in 19 (33%) of 58 patients with LCA. These represent nine
different previously identified and four novel sequence vari-
ants. We identified one heterozygous pathologic LCA variant in
patient 3460V1 among 58 patients with LCA. Possibly, muta-
tions outside the protein coding exons and their immediate
vicinity were missed, as are all heterozygous deletions. Also,
the heterozygous variant in 3460V1 could be unrelated to LCA,
since the aggregate heterozygosity frequency of mutations in
the AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1 genes
in the general population is 1.3%, assuming an LCA incidence
of 1 in 100,000 (Cremers FPM, unpublished data, 2005).
In 13 families, segregation analysis of the sequence variants
was compatible with autosomal recessive inheritance. In five
other families in whom no segregation analysis could be per-
formed, three patients apparently were homozygous for a dis-
ease-causing sequence change. However, the presence of het-
erozygous deletions cannot be ruled out in these cases.
Mutations in this patient cohort were most frequently iden-
tified in CRB1 (nine cases, 15.5%), followed by GUCY2D (six
cases, 10.3%), AIPL1 (three cases, 5.2%), and RPE65 (one case,
1.7%). No pathologic mutations were found in CRX, RDH12
(in 22 patients), and RPGRIP1. The infrequent involvement of
CRX, RDH12, and RPGRIP1 in LCA is in accordance with the
results of previous studies.6,8,27,30 In addition, it is noteworthy
that RPE65 seems to account for only a minority of cases
(1.7%) in comparison to reported frequencies in other studies
of 3% to 15%.31–34 This variation may be due to the relatively
small patient cohort, the variable mutation detection strategies
and the variable inclusion criteria applied by different groups.
In general, mutations in the RPE65 gene are more frequently
observed in patients with early-onset RP rather than LCA.35
(Yzer S, unpublished results, 2005).
All three patients carrying AIPL1 mutations were homozy-
gous for the p.W278X allele. Previously, nine patients from
different ethnic backgrounds were described to be homozy-
gous for this change by Dharmaraj et al.36 The phenotype of
these patients consisted of severe night blindness, some degree
of maculopathy, attenuated vessels, and spicular intraretinal
pigment migration in the periphery after several years of evo-
lution. Keratoconus was observed in 6 of 19 patients with
distinct AIPL1 mutations. The patients described in this study
showed an apparently normal fundus on initial examination,
which progressively evolved into peripheral spicular intrareti-
nal pigment migration in early childhood. High hyperopia and
a very poor visual acuity appear to be consistent findings. Night
blindness is a frequent, albeit variable, characteristic.6,36
Eight of nine patients with CRB1 mutations showed either
all or some funduscopic characteristics of the RP12 phenotype,
including relatively normal optic discs and vessels, a distinct
maculopathy, and a nummular rather than a spicular type of
pigmentation. Yellow-white retinal dots were present in eight
patients and PPRPE in three. Findings less frequently observed
in RP12 or patients with CRB1 mutations, such as Coats-like
exudative vasculopathy, vascular sheathing, optic disc edema,
macula dysplasia, and keratoconus were also observed in our
patients. Moderate to high hyperopia and nystagmus are also
associated with CRB1-associated LCA.4,6,8,37 This RP12 pheno-
type is easily distinguishable from other RP-like phenotypes.
The CRX p.Y142C variant has been identified in heterozy-
gous form in a patient with autosomal dominant LCA (Kaplan
J, personal communication, 2004). In our cohort, one patient
from a consanguineous marriage was a heterozygous carrier of
this variant. Sequence analysis revealed the healthy mother to
be homozygous for this sequence change, suggesting that the
p.Y142C change is nonpathogenic. Because the maternal
grandparents had normal vision, a metabolic interference
model in which homozygous mutations abolish each other’s
pathologic effects, seems unlikely.
Mutations in the GUCY2D gene in LCA were first reported
in Mediterranean families.10 In the LCA cohort of this study,
the p.R768W mutation was found in eight of 12 (67%) alleles.
Four of the five patients carrying this allele were of Belgian or
Dutch origin, and the fifth was of Belgian/Moroccan descent.
Segregation analysis showed that the p.R768W allele came
from her Belgian mother. Hanein et al.6 found the p.R768W
allele in only 1 of 75 GUCY2D alleles in 38 patients, most of
which were from Mediterranean countries. This difference in
frequency of the p.R768W mutation may be suggestive of a
founder effect in the northwestern region of Europe. The three
patients with the homozygous p.R768W GUCY2D mutation
are severely affected, did not show light perception at initial
examination, and had no signs of improvement later in life. In
most patients, the initial fundus was normal which, later in life,
showed attenuated vasculature and subtle pigmentations. In
accordance with previous findings by Dharmaraj et al.,30 re-
fraction in GUCY2D-related patients with LCA varies from mild
to severe hyperopia with VA showing a spectrum from no light
perception to 0.1. In contrast, Hanein et al.6 generally found
hypermetropia ( 7).
A novel frameshift mutation, p.F530fs, was identified in the
RPE65 gene in a patient heterozygous for p.R124X. The phe-
notype of this patient is similar to previously published phe-
notypes with very poor visual acuity early in life that gradually
improves, myopia, and some residual visual field function.
Overall, the phenotype of patients with LCA with RPE65 mu-
tations seems relatively mild in comparison to other forms of
LCA.6,34,35
Our patient cohort was relatively small, but our clinical data
suggest that patients with homozygous p.W278X AIPL1 muta-
tions have a very poor visual acuity, with hyperopia and an
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initially normal fundus, which progresses to an RP-like fundus
in early childhood. In general, GUCY2D-related LCA results in
the most severe visual impairment with a relatively normal
fundus in the mid-20s. Furthermore, this study supports the
existence of a fairly typical and consistent phenotype of CRB1-
associated LCA, including a maculopathy ranging from macular
RPE alterations to macular aplasia, fine white sub- or deep
intraretinal drusen-like deposits, and nummular rather than
spicular hyperpigmentation in both the macula and periphery.
The phenotypical data also confirm that PPRPE is a rather
inconsistent feature in patients with CRB1mutations, probably
due to its transient nature.
In this study, CRB1 was the most frequently involved gene
(9/19 patients) in a cohort of predominantly Belgian and Dutch
patients. In a Spanish LCA cohort, mutations in CRB1 turned
out to underlie two thirds of all cases with mutations in the
known LCA genes (Vallespin E, personal communication,
2005). In contrast, no CRB1 mutations were detected in a
Canadian cohort of 24 patients with LCA, suggestive of sizeable
geographic differences in the occurrence of mutations.38
Taken together, the clinical findings in our patients suggest
that both photophobia and night blindness do not seem to be
reliable clinical features that can be used to direct gene analy-
sis, as was proposed by Hanein et al.6 Indeed, within the
AIPL1-, GUCY2D-, and CRB1-associated patient cohorts in our
study, both photophobia and night blindness were noted.
A comprehensive mutation analysis study of all currently
known LCA genes has been performed.6 Excluding this study’s
findings in the TULP1 gene, as the TULP1 gene was not
analyzed in our study, mutations were identified in 44.4% of
the disease alleles by using a combination of linkage analysis of
known genes, denaturing high-pressure liquid chromatography
mutation scanning, and direct sequencing. Our approach (i.e.,
a first-pass mutation detection of known mutations with the
LCA microarray chip followed by sequence analysis of patients
with heterozygous mutations) allowed the detection of 31.9%
(37/116) of disease alleles. Hence, approximately 72% (31.9/
44.4) of the expected disease alleles were identified with a
relatively small effort. We therefore believe that the LCA mu-
tation chip offers a cheap and efficient first-pass screening test.
This robust technique is generally applicable and allows more
carefully directed efforts of subsequent standard sequence
analysis. Furthermore it is independent of a detailed clinical
history necessary for a decisional molecular diagnostic flow-
chart, as outlined by Hanein et al.6 Finally, by regular addition
of newly identified alleles, the efficiency of the microarray will
continuously improve.
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